AUG 1 6 2007

Hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: Aug, 14, 2007 Signature: Deborat Clark)

Docket No.: 5138 [66816(54716)] (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Deepa Eveleigh et al.

Application No.: 10/675,406

Filed: September 30, 2003

.

METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND

MONITORING CANCER THERAPY

Confirmation No.: 7796

Art Unit: 1642

Examiner: C. Joyce

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

08/16/2007 HDEMESS1 00000019 041105 10675406

01 FC:1806

180.00 DA

Dear Sir:

For:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicant(s) have become aware of the following documents, cited in a Supplementary Partial European Search Report issued <u>June 1, 2007</u>, during the prosecution of European Patent Application No. 03781302.9 which corresponds to the above-referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit(s) these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the Supplementary Partial European Search Report and of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well.

233940

Application No.: 10/675,406

2

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed after the mailing date of a Final Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

I hereby certify, pursuant to 37 CFR 1.97(e)(1), that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Furthermore, in accordance with 37 CFR 1.704(d), Applicant(s) note(s) that to our knowledge this communication was not received by any individual designated in 1.56(c) more than thirty days prior to the filing of this statement.

Please charge our Deposit Account No. 04-1105 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our

Application No.: 10/675,406

3

Deposit Account No. 04-1105, under Order No. 66816(54716). A duplicate copy of this paper is enclosed.

Respectfully submitted,

Date: August 14,20

William F. Gray, Esq.
Attorney for Applicant(s)
Reg. No. 31,018

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516-4175

Phone (203) 812-2712

By:

Marina Heusch, Ph.D Agent for Applicants Registration No.: 47,647

EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874 Boston, MA 02205

Telephone: 203-975-7505 Facsimile: 203-975-7180

Substitute for form 1449/PTO			-	Complete if Known		
	State to form 1410/110			Application Number	10/675,406-Conf. #7796	
11	NFORMATION	N DIS	SCLOSURE	Filing Date	September 30, 2003	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Deepa Eveleigh	
				Art Unit	1642	
	(Use as many sh	eets as	necessary)	Examiner Name	C. Joyce	
Sheet	1	of	1	Attorney Docket Number	5138 [66816(54716)]	

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
	AA	US-5,486,456	01/23/1996	Xu et al	
	AB	US-5,830,703	11/03/1998	Kitamura et al	
	AC	US-6,238,875	05/29/2001	Altieri	
	AD	US-6,320,022	11/20/2001	Cutitta et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY			
	ВА	WO 02/28999	04/11/2002	Gene Logic, Inc.		
	ВВ	AU 746502	02/09/1999	The Scripps Research Institute		
	ВС	EP 1036845	09/20/2000	Affymetrix, Inc.		
	BD	FR 2821080	08/23/2002	Sanofi-Synthelabo		
	BE	WO 2004/065577	08/05/2004	Bristol-Myers Squibb Company		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		

^{*}EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

AUG 16 2007 W

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

o.s. Patent and Trademark Office, o.s. DEPARTMENT OF COMMERCE of the Commerce

Application No. (if known): 10/675,406

Attorney Docket No.: 5138 [66816(54716)]

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on <u>August 14, 2007</u>
Date

Signature

Deborah Clark

Typed or printed name of person signing Certificate

(617) 439-4444

Registration Number, if applicable

Telephone Number

Note:

Each paper must have its own certificate of mailing, or this certificate must identify

each submitted paper.

IDS (Citation) by Applicant (9 References) (1 page) Supplemental Information Disclosure Statement (3 pages)

Transmittal (1 page)

Charge \$180.00 to deposit account 04-1105

PTO/SB/21 (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
OF A DEPARTMENT OF COMMERCE
OF A

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/675,406-Conf. #7796 Filing Date September 30, 2003 First Named Inventor Deepa Eveleigh Art Unit 1642 Examiner Name C. Joyce Attorney Docket Number 5138 [66816(54716)]

ENCLOSURES (Check all that apply)					
X Fee Transmittal Form		Drawing(s)	After Allowance Communication to TC		
Fee Atta	ached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences		
Amendment/R	Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Fir	nal	Petition to Convert to a Provisional Application	Proprietary Information		
Affidavit	ts/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter		
Extension of 1	Γime Request	Terminal Disclaimer	X Other Enclosure(s) (please Identify below):		
Express Aban	ndonment Request	Request for Refund	Return Receipt Postcard		
X Information Di	isclosure Statement	CD, Number of CD(s)			
Certified Copy Document(s)	of Priority	Landscape Table on CD			
Reply to Missing Parts/ Incomplete Application		Remarks			
Reply to Missing Parts under 37 CFR 1.52 or 1.53					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name B	BAYER PHARMACEUTICALS CORPORATION				
Signature William Gray					
Printed name W	Printed name William F. Gray, Ph.D.				
Date /	August 14, 2007 Reg. No. 31,018				

Marina Heusch, Ph.D. (Reg. No.: 47,647) Attorney/Agent for the Applicants